Cognition Therapeutics (NASDAQ:CGTX) Given Buy Rating at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Cognition Therapeutics (NASDAQ:CGTX) in a report released on Friday morning,Benzinga reports. Chardan Capital currently has a $11.00 target price on the stock.

CGTX has been the subject of a number of other research reports. B. Riley reaffirmed a “neutral” rating and set a $1.00 target price (down previously from $5.00) on shares of Cognition Therapeutics in a report on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Cognition Therapeutics in a research note on Monday, November 4th. Finally, Cantor Fitzgerald downgraded shares of Cognition Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, July 30th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Cognition Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Cognition Therapeutics Price Performance

NASDAQ CGTX traded down $0.05 during midday trading on Friday, hitting $0.46. 336,050 shares of the company traded hands, compared to its average volume of 493,689. The company has a market cap of $18.51 million, a PE ratio of -0.48 and a beta of 1.34. The company’s 50-day simple moving average is $0.50 and its 200-day simple moving average is $1.21. Cognition Therapeutics has a 52 week low of $0.34 and a 52 week high of $2.95.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Bangor Savings Bank lifted its position in shares of Cognition Therapeutics by 41.6% during the 2nd quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock valued at $56,000 after buying an additional 10,000 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in Cognition Therapeutics by 33.4% during the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after purchasing an additional 24,050 shares in the last quarter. CM Management LLC lifted its holdings in Cognition Therapeutics by 14.3% during the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $332,000 after purchasing an additional 25,000 shares in the last quarter. Sigma Planning Corp grew its position in shares of Cognition Therapeutics by 14.6% in the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after purchasing an additional 25,050 shares during the period. Finally, Tocqueville Asset Management L.P. purchased a new stake in shares of Cognition Therapeutics during the first quarter worth about $47,000. Institutional investors and hedge funds own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.